Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 114, Issue 7, Pages 737-743
Publisher
Springer Nature
Online
2016-03-30
DOI
10.1038/bjc.2016.45
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.
- (2017) Pascal Hammel et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic Adenocarcinoma
- (2017) Margaret A. Tempero et al. Journal of the National Comprehensive Cancer Network
- Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma
- (2015) Moh'd Khushman et al. PANCREATOLOGY
- Pancreatic cancer and FOLFIRINOX: a new era and new questions
- (2015) Robert De W. Marsh et al. Cancer Medicine
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience
- (2013) J. E. Faris et al. ONCOLOGIST
- A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
- (2012) Peter J Hosein et al. BMC CANCER
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
- (2012) Sophie Gourgou-Bourgade et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity
- (2012) Krishna S. Gunturu et al. MEDICAL ONCOLOGY
- FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy
- (2011) F L Day et al. BRITISH JOURNAL OF CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
- (2009) Mark P. Callery et al. ANNALS OF SURGICAL ONCOLOGY
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- (2009) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started